Pembrolizumab benefits patients with brain metastases
Pembrolizumab benefits patients with brain metastases
Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma
ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows promising efficacy
Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens
A randomised trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML
Single infusion of cilta-cel sees longer median PFS than any previously reported therapy in heavily pretreated RRMM
Atezolizumab, obinutuzumab and venetoclax combination is active and leads to durable remissions in previously untreated DLBCL-RS
Addition of blinatumomab to mini-hyper-CVD and inotuzumab improves outcomes in R/R ALL
Chemotherapy-free combination of ponatinib and blinatumomab results in high rates of CMR and NGS MRD negativity in Ph positive ALL
Ponatinib superior to imatinib in combination with reduced-intensity chemotherapy in newly diagnosed Ph positive ALL
Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma
Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction